Plain-English translation of NCT07354711 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial testing a new medication called , which is designed to attack cancer cells in people with advanced lung or stomach cancer. The study will first test different doses of the medication to find the safest and most effective amount, and then test that dose in a larger group of patients. Researchers want to understand how well this treatment works and what side effects it may cause.
Advanced lung and stomach cancers that have spread or cannot be surgically removed are very difficult to treat and often have poor outcomes. This trial exists to find out if this new medication—which works differently than many existing treatments—can help patients with these cancers live longer and healthier lives.
You likely qualify if…
You likely don't qualify if…
In the first stage, you would receive increasing doses of the medication to help doctors determine the safest dose. In the second stage, a larger group of patients would receive the dose identified as safest and most promising. You would need to attend regular clinic visits for blood tests, scans, and physical exams to monitor how you are responding to the treatment and track any side effects. The exact schedule will depend on the study protocol, but you should be prepared for frequent appointments early on.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China